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Detecting Preclinical
Cardiomyopathy in
Duchenne Muscular Dystrophy?*
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Houston, Texas
Dystrophin is a key linker protein between the sarcolemma
of the myocyte and the contractile apparatus, the sarcomere
(1,2). When dystrophin is deficient, various clinical pheno-
types may develop, the most devastating of which is Duch-
enne muscular dystrophy (DMD) (3). This disorder is
characterized predominantly by skeletal muscle disease that
presents early in life and rapidly progresses to require a
wheelchair before age 11 years (4). The disorder affects
1:3,500 male births, having X-linked recessive inheritance,
and female carriers may also develop milder disease later in
life (3,4). In addition to severe progressive skeletal myop-
athy, nearly all affected boys will eventually develop a dilated
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cardiomyopathy (DCM) and congestive heart failure
(CHF), usually during or after puberty (5). Dystrophin
mutations that cause DMD are typically deletion mutations
that are “out of frame” (i.e., the deletion disrupts the
3-nucleotide codon, which encodes an amino acid, causing
the deoxyribonucleic acid reading frame to encode the
wrong amino acids after the deleted region), resulting in a
dysfunctional protein (6). Other forms of disease caused by
dystrophin deficiency include the milder muscular dystrophy
called Becker muscular dystrophy (BMD), with later onset,
slower progression (wheelchair-bound after age 16 years) of
skeletal myopathy, and DCM, which may be severe (6).
Deletion mutations are also common but typically are
“in-frame” (6). Other forms of dystrophinopathies include
X-linked dilated cardiomyopathy (XLCM), (7–9) with
severe, progressive DCM and elevated muscle creatine
kinase (CK-MM) but without clinically evident myopathy,
as well as myalgia and CK-emia.
The onset of DCM in DMDmost typically occurs during
or after puberty, most commonly between 14 to 16 years of
age (5,8). The DCM may be severe and progressive, with
life-threatening heart failure and/or arrhythmias, or may be
asymptomatic for many years without clinical features. The
standard diagnostic evaluation of cardiac involvement, the
echocardiogram, is a noninvasive method of evaluating
left ventricular (LV) size and systolic function, with the
ability to analyze a variety of more subtle parameters. In
most centers, individuals affected with DMD obtain
echocardiograms after symptoms of heart failure begin.
Unfortunately, this approach may lead to irreversibly
progressive disease, ending in death. Hence, the concept
of early referral and a noninvasive imaging approach that
identifies early disease could be a more useful methodol-
ogy with better long-term outcomes. Clearly, new ap-
proaches that enable early, presymptomatic diagnostic
capability would be useful.
In this issue of the Journal,Giglio et al. (10) report on the
use of noninvasive ultrasonic tissue characterization (UTC)
analysis (11, 12) of the myocardium of children with DMD
under 10 years of age. Previously, Mori et al. (13) used the
same methodology to study older patients with DMD (17.6
 2.7 years) with overt DCM and demonstrated consistent
abnormalities compared to normal controls, suggesting this
method was useful in the diagnostic cardiovascular evalua-
tion of these patients. Giglio et al. (10) took this one step
further, seeking early detection of myocardial physical prop-
erty changes in children with no signs or symptoms of
cardiac involvement, including normal electrocardiograms
and normal LV size and systolic function indexes. Patients
and controls displayed significantly different UTC parame-
ters, and interindividual differences were larger in DMD
patients than in controls as well. Based on their results, the
investigators (10) suggest that this method demonstrates
subtle involvement of the myocardium early in DMD and
could be potentially useful and reliable in assessing myocar-
dial changes over time.
The work described has several potential important fea-
tures that should be highlighted. First, essentially all pa-
tients with dystrophin deficiency are at risk for the devel-
opment of DCM (5) and should be screened by noninvasive
methods. The earlier that individuals are screened, the
better, allowing early diagnosis and therapeutic interven-
tion. Female carriers are also at risk and should be screened
(5). The method outlined by Mori et al. (13) and Giglio et
al. (10) should be considered in children and adults, includ-
ing female carriers, in order to follow individuals with
dystrophin deficiency before symptoms develop. Another
important use of the method could include longitudinal
studies assessing drug therapy response in these patients that
might help answer the question of whether institution of
therapy should be considered before abnormal echocardio-
grams develop.
We have been studying children through the use of
echocardiography and cardiac magnetic resonance imaging;
the children are evaluated starting at 10 years of age and are
evaluated longitudinally on a yearly basis, with therapeutic
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intervention using angiotensin-converting enzyme inhibi-
tors and beta-blockers at the earliest signs of myocardial
disease. In a high percentage of cases, both reverse remod-
eling and normalization of LV size and systolic function
rapidly occur using this approach. It is possible that earlier
use of these agents would be beneficial as these patients are
“destined” to develop cardiac disease. Perhaps UTC analysis
will answer this question.
The potential improvement in the care of DMD patients
attributable to the development of UTC analysis is exciting.
Perhaps more exciting, however, is the possibility that this
method could be used more globally for other skeletal
myopathies and cardiomyopathies. We have suggested pre-
viously that a “final common pathway” for myocardial
disorders exist, with the cytoskeletal links between sarco-
lemma and sarcomere being critical (14,15). In addition, we
have raised the possibility that “muscle is muscle” because
the majority of the genes identified as DCM-causing
have a parallel skeletal myopathy phenotype and the
majority of skeletal myopathies have associated DCM
(16). Thus, it is possible that UTC can also be useful in
determining at-risk myocardium in these disorders. It is
hoped that the answer to the question of whether UTC is
“a noninvasive means of detecting preclinical cardiomy-
opathy in DMD” will be shown to be true and extended
to these other disorders, improving the care and out-
comes of these difficult diseases.
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